Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Schering-Plough_Corporation
|
| gptkbp:activities |
gptkb:weapon
|
| gptkbp:approves |
gptkb:1999
gptkb:FDA |
| gptkbp:availability |
prescription only
|
| gptkbp:can_be_used_with |
radiation therapy
other chemotherapy agents |
| gptkbp:clinical_trial |
Phase II
Phase III |
| gptkbp:contraindication |
pregnancy
breastfeeding severe bone marrow suppression hypersensitivity to temozolomide |
| gptkbp:excretion |
urine
|
| gptkbp:formulation |
gptkb:beer
injection |
| https://www.w3.org/2000/01/rdf-schema#label |
Temodar
|
| gptkbp:indication |
malignant glioma
recurrent glioblastoma |
| gptkbp:ingredients |
temozolomide
C6 H6 N4 O2 |
| gptkbp:is_atype_of |
L01 A X03
|
| gptkbp:is_monitored_by |
kidney function
liver function blood counts |
| gptkbp:is_used_for |
treating anaplastic astrocytoma
treating glioblastoma |
| gptkbp:lifespan |
1.5 hours
3 hours (after multiple doses) |
| gptkbp:manager |
oral
intravenous |
| gptkbp:manufacturer |
gptkb:Merck_&_Co.
|
| gptkbp:metabolism |
liver
|
| gptkbp:previous_name |
temozolomide
|
| gptkbp:price |
varies by location
|
| gptkbp:products |
Dacogen
Alkylating agents |
| gptkbp:side_effect |
fatigue
headache nausea vomiting diarrhea constipation hair loss loss of appetite increased risk of infection |
| gptkbp:storage |
room temperature
protected from moisture |
| gptkbp:traded_on |
Temozolomide
|
| gptkbp:type_of |
85622-93-1
|
| gptkbp:type_of_care |
important for effectiveness
|
| gptkbp:weight |
194.19 g/mol
|